Short answer
Ceribell, Inc. (CBLL) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $23M (down 51.8% year over year) with net income of −$13M.
Q3 2025 key financials · XBRL
- Revenue
- $23M
- −51.8% YoY · +6.6% QoQ
- Net income
- −$13M
- +51.7% YoY · +1.3% QoQ
- Operating margin
- -64.8%
- Gross margin
- 88.3%
- EPS (diluted)
- −$0.37
- +92.6% YoY · +0.0% QoQ
Source: XBRL data from the Ceribell, Inc. (CBLL) Q3 2025 10-Q on SEC EDGAR. USD.
Ceribell, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material changes identified; filing text omits the substantive Risk Factors section
- Liquidity risk: cash and marketable securities declined to $168.5 million from $194.4 million cash at December 31, 2024
- Regulatory risk: medical-device compliance failures could trigger product-market restrictions and materially harm results
- Supply-chain risk: key product subassemblies depend on contract manufacturers in China and Vietnam
- Market risk: inflation and supply-chain pressures may raise costs without corresponding price increases, pressuring margins
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Ceribell, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.